{"id":"NCT03191799","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors","officialTitle":"A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-05","primaryCompletion":"2020-11-19","completion":"2020-11-19","firstPosted":"2017-06-19","resultsPosted":"2021-06-11","lastUpdate":"2021-06-11"},"enrollment":195,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"DRUG","name":"Emicizumab","otherNames":["Hemlibra","RO5534262","ACE910"]}],"arms":[{"label":"1.5 mg/kg Emicizumab QW","type":"EXPERIMENTAL"}],"summary":"This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.","primaryOutcome":{"measure":"Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale","timeFrame":"From Baseline until study completion (up to 2 years)","effectByArm":[{"arm":"1.5 mg/kg Emicizumab QW","deltaMin":163,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":72,"countries":["Australia","Belgium","Brazil","Canada","Colombia","Finland","Germany","Guatemala","Hungary","India","Israel","Italy","Mexico","Netherlands","Panama","Poland","Portugal","Romania","Russia","Saudi Arabia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["38222041"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":193},"commonTop":["ARTHRALGIA","NASOPHARYNGITIS","HEADACHE","INJECTION SITE REACTION","PYREXIA"]}}